Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bayer

OTC:BAYRYPharma

Leverkusen, North Rhine-Westphalia, Germany · Est. 1863 · 100,000 employees

Bayer is a multinational pharmaceutical and life sciences company focused on human and animal health, crop science, and consumer health products.

22

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

23

Indications↗

Distinct diseases across all programs

1,650

Clinical Trials↗

All sponsored trials (all statuses)

76

Orange Book Patents

Across 15 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

22 drugs in development

Phase 32

Phase 24

Phase 17

Preclinical11

By Therapeutic Area

top 6

Oncology

1456%

Nephrology

312%

Cardiovascular

14%

Infectious Disease

14%

Metabolic & Endocrine

14%

Ophthalmology

14%

R&D Momentum

84/100

Pipeline Velocity

61/100

Trial Completion Rate

92/100

Pipeline Concentration

36/100

Pipeline Freshness

75/100

Strategic Signals

↗Active in Cardiovascular but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

An Open-label, Non-randomized, Multi-center, Phase 4 Pharmacokinetic Study to Evaluate the Systemic Exposure After Bilateral Intravitreal Administration of High Dose (8 mg) Aflibercept in Adults With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

Study to Investigate Renal Functional Reserve in Healthy Participants and in Participants With Impaired Renal Function.

Active, not recruiting

A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome

Active, not recruiting

An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.

Retrospective, Non-interventional Database Study for the Evaluation of Real-world Drug Use Patterns, Clinical Characteristics and Clinical Outcomes in Patients Initiated on Vericiguat in India

Active, not recruiting

A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of ARPI

Methodology Study in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass to Investigate Mechanisms Involved in Cardiac Surgery-associated Acute Kidney Injury.

A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)

A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A

Details

Company Info

Company Overview

$55.0B

Mkt Cap

$46.0B

Revenue

—

Cash

CEOBill Anderson

Founded1863

Employees100,000

HQLeverkusen, North Rhine-Westphalia, Germany

ExchangeOTC:BAYRY

Websitebayer.com

LinkedInCompany Page

Therapeutic Focus

OncologyOtherCardiovascularInfectious DiseaseMetabolic & EndocrineRespiratoryNephrologyOphthalmologyGastroenterologyNeurologyImmunologyHematologyRare DiseaseDermatologyMusculoskeletalPsychiatry

Patent Expirations

40 patent groups across drugs · Source: FDA Orange Book

DrugExpires

LynkuetSep 15, 2026 AdempasDec 4, 2026 LevitraJul 23, 2027 NexavarDec 24, 2027 NexavarSep 10, 2028 LevitraDec 23, 2028 Cipro4 patentsApr 21, 2029 Avelox2 patentsMay 29, 2029

32 more

Vitrakvi8 patentsOct 21, 2029 AliqopaOct 22, 2029 CiproApr 27, 2030 StivargaJun 2, 2030 Nubeqa3 patentsOct 27, 2030 Stivarga2 patentsFeb 16, 2031 Aliqopa2 patentsMar 29, 2032 StivargaJul 9, 2032 Bayer Aspirin4 patentsSep 29, 2032 NubeqaMar 25, 2033 KerendiaAug 26, 2033 Adempas3 patentsFeb 18, 2034 CiproJul 1, 2035 KerendiaJul 29, 2035 HyrnuoOct 10, 2035 Vitrakvi4 patentsNov 16, 2035 Nubeqa3 patentsJan 28, 2036 LynkuetMay 18, 2036 Ambelvist4 patentsMay 29, 2036 VitrakviAug 15, 2036 Vitrakvi7 patentsApr 4, 2037 CiproNov 12, 2037 NubeqaFeb 27, 2038 CiproNov 27, 2038 Lynkuet3 patentsMar 13, 2039 AmbelvistNov 20, 2039 AmbelvistMay 18, 2040 NubeqaJul 2, 2040 LotriminMay 26, 2042 NubeqaJun 17, 2042 HyrnuoNov 13, 2043 LynkuetMay 14, 2045

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

—

—

1

—

Cardiovascular(1 drug)

Infectious Disease(1 drug)

—

1

—

—

—

Infectious Disease(1 drug)

Metabolic & Endocrine(1 drug)

1

—

—

—

—

Metabolic & Endocrine(1 drug)

Nephrology(3 drugs)

—

—

3

—

—

Nephrology(3 drugs)

Oncology(14 drugs)

7

6

1

1

—

Oncology(14 drugs)

Ophthalmology(1 drug)

1

—

—

—

—

Ophthalmology(1 drug)

Unknown / Other(4 drugs)

4

1

—

—

—

Unknown / Other(4 drugs)

Regulatory

Regulatory Timeline

20211 event

FDANov 11

Cipro — CIPRO

Application NDA019537

20223 events

FDANov 23

Vitrakvi — VITRAKVI

Application NDA210861

FDANov 23

Vitrakvi — VITRAKVI

Application NDA211710

FDASep 1

Kerendia — KERENDIA

Application NDA215341

20234 events

FDANov 3

Vitrakvi — VITRAKVI

Application NDA210861

FDANov 3

Vitrakvi — VITRAKVI

Application NDA211710

FDAAug 28

Nexavar — NEXAVAR

Application NDA021923

FDAAug 28

Nexavar — NEXAVAR

Application NDA021923

20242 events

FDASep 20

Cipro — CIPRO

Application NDA020780

FDASep 20

Cipro — CIPRO

Application NDA019537

20258 events

FDANov 19

Hyrnuo — HYRNUO

Application NDA219972 (NDA)

FDAOct 24

Lynkuet — LYNKUET

Application NDA219469 (NDA)

FDASep 26

Lotrimin — CLOTIC

Application NDA217628 (NDA)

FDASep 26

Gyne-Lotrimin 3 Combination Pack — CLOTIC

Application NDA217628 (NDA)

FDAJul 11

Kerendia — KERENDIA

Application NDA215341

FDAApr 9

Vitrakvi — VITRAKVI

Application NDA210861

FDAApr 9

Vitrakvi — VITRAKVI

Application NDA211710

FDAFeb 25

Stivarga — STIVARGA

Application NDA203085

20262 events

FDAJun 11

Ambelvist — AMBELVIST

Application NDA219627 (NDA)

FDAFeb 3

Stivarga — STIVARGA

Application NDA203085

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)